RecruitingPhase 2Drug trialNeoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC PatientsTo evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS\>10 in the biopsy samples.